本文采用的英格恩产品: 增强型ECL发光液, 超敏ECL发光液
Down-regulation of P-gp expression and function after Mulberroside A treatment: potential role of protein kinase C and NF-kappa B.
Li Y1, Huang L2, Zeng X1, Zhong G1, Ying M1, Huang M3, Bi H4.
Author information
1School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province 510006, PR China.2School of Pharmaceutical Sciences, Hainan Medical University, Haikou, Hainan Province 571199, PR China.3School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province 510006, PR China. Electronic address: huangmin@mail.sysu.edu.cn.4School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province 510006, PR China. Electronic address: bihchang@mail.sysu.edu.cn.
Abstract
P-Glycoprotein (P-gp) plays a major role in drug-drug and herb-drug interactions. Mulberroside A (Mul A) is one of the main bioactive constituents of Sangbaipi, the dried root-bark of Morus alba L. (white mulberry), which is officially listed in the Chinese Pharmacopoeia. In the present study, we investigated the effect of Mul A treatment on mRNA expression and protein expression of P-gp in the Caco-2 cells by real-time qPCR and Western blot analysis. The effect of Mul A treatment on the function of P-gp in vitro and in vivo was assessed by Rho123 transport assay and a pharmacokinetic study. The potential roles of protein kinase C (PKC) and nuclear factor kappa B (NF-κB) in the expression regulation of P-gp after Mul A treatment were also investigated. The results revealed that Mul A treatment significantly decreased the mRNA and protein expression of P-gp in Caco-2 cells after treatment with Mul A (5-20 μM). Furthermore, Mul A treatment displayed apparently inhibitory effect on the function of P-gp both in vitro and in vivo. In addition, activation of PKC activity and NF-κB nuclear translocation were observed in the presence of Mul A, which suggested that PKC and NF-κB might play crucial roles in Mul A-induced suppression of P-gp. Our study demonstrated that Mul A treatment could down-regulate P-gp expression and function accompanied by the activation of PKC and NF-κB, and this should be taken into consideration in potential herb-drug interactions when Mul A or M. alba are co-administered with other drugs transported by P-gp.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
KEYWORDS:
Digoxin; Herb–drug interaction; Mulberroside A; Nuclear factor kappa B; P-Glycoprotein; Protein kinase C